MedPath
HSA Approval

MERO-AFT POWDER FOR INJECTION 1000MG/VIAL

SIN17069P

MERO-AFT POWDER FOR INJECTION 1000MG/VIAL

MERO-AFT POWDER FOR INJECTION 1000MG/VIAL

August 26, 2024

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAVENOUS

Medical Information

J01DH02

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

Qilu Antibiotics Pharmaceutical Co.,Ltd

Active Ingredients

Meropenem trihydrate eqv Meropenem

1000 mg/vial

Meropenem

Documents

Package Inserts

Mero-AFT Powder for Injection PI.pdf

Approved: August 26, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MERO-AFT POWDER FOR INJECTION 1000MG/VIAL - HSA Approval | MedPath